Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of the American Medical Association (JAMA)

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1001/jama.2016.1252PMID 26934259
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Glucagon‐like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta‐analysis

  2015cited by this paper
• Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

  2014cited by this paper
• Missing data sensitivity analysis for recurrent event data using controlled imputation

  2014cited by this paper
• Clinical Trials with Missing Data: A Guide for Practitioners

  2014cited by this paper
• Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)

  2014cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2014cited by this paper
• Glycemic control among patients with type 2 diabetes who initiate basal insulin: a retrospective cohort study

  2014cited by this paper
• Analysis of hypoglycemic events using negative binomial models

  2013cited by this paper
• Optimization of insulin therapy in patients with Type 2 diabetes mellitus: beyond basal insulin

  2012cited by this paper
• Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study

  2012cited by this paper
• Type 2 Diabetes Care and Insulin Intensification

  2011cited by this paper
• Encyclopedia of research design

  2010cited by this paper
• Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

  2009cited by this paper
• Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

  2009cited by this paper
• Barriers to insulin initiation and intensification and how to overcome them

  2009cited by this paper
• Comments on ‘Current issues in non‐inferiority trials’ by Thomas R. Fleming, Statistics in Medicine, DOI: 10.1002/sim.2855

  2008cited by this paper
• Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes

  2006cited by this paper
• Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens.

  2005cited by this paper
• BRIEF REPORT: The burden of diabetes therapy

  2005cited by this paper

• Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies.

  2026cites this paper
• Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in the Management of Diabetes Mellitus: A Review

  2025cites this paper
• Analysis of the long-term impact of glucagon-like peptide-1 (GLP-1) receptor agonists for control of obesity and obesity-related comorbidities: a meta-analysis

  2025cites this paper
• Treatment of type 2 diabetes mellitus - a current view of the different drug classes and strategies for their use

  2025cites this paper
• Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.

  2025cites this paper
• An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP‐1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes

  2025influential citation
• The impact of ideglira in treatment simplification in older adults with type 2 diabetes mellitus already on insulin therapy: The stop study.

  2025cites this paper
• Bridging Evidence and Practice: A Consensus Statement from the Korean Diabetes Association on Diabetes Screening, Pharmacological Treatment and Severe Diabetes

  2025cites this paper
• Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?

  2025cites this paper
• Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial

  2025cites this paper
• 2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association

  2025cites this paper
• Efficacy and hypoglycaemia outcomes with once‐weekly insulin icodec versus once‐daily basal insulin in type 2 diabetes according to baseline glucagon‐like peptide‐1 receptor agonist and sodium‐glucose co‐transporter‐2 inhibitor use: A post hoc analysis of ONWARDS 1–5

  2025cites this paper
• Long‐term effectiveness of iGlarLixi treatment in people with type 2 diabetes in the United States: The soli‐durability 24‐month observational study

  2025cites this paper
• Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.

  2025cites this paper
• The influence of the glucagon‐like peptide‐1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial

  2025cites this paper
• INNOVATIONS IN DIABETES MELLITUS MANAGEMENT: A REVIEW OF USFDA-APPROVED DRUGS AND PHASE 3 CLINICAL TRIALS.

  2024cites this paper
• Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review

  2024cites this paper
• IDegLira improves time in range in a cohort of patients with type 2 diabetes: TiREX study

  2024influential citation
• IDegLira for the real‐world treatment of type 2 diabetes in Italy. Final results from the REX observational study

  2024cites this paper
• SPIRIT: Assessing Clinical Parameters Associated with Using IDegLira in Patients with Type 2 Diabetes in a Real-World Setting in Colombia

  2024cites this paper
• The User's Guide to the Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update.

  2024cites this paper
• Effectiveness, Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes: A 4-Year Follow-Up Real-World Study

  2024cites this paper
• Expert Opinion on Optimising Type 2 Diabetes Treatment Using Fixed-Ratio Combination of Basal Insulin and GLP-1 RA for Treatment Intensification and Simplification

  2024cites this paper
• The Current and Future Role of Insulin Therapy in the Management of Type 2 Diabetes: A Narrative Review

  2024cites this paper
• Фиксированные комбинации агонистов рецепторов ГПП-1 и базального инсулина: обзор литературы

  2024cites this paper
• 2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association

  2024cites this paper
• IDegLira for type 2 diabetes: a systematic review and meta-analysis

  2023cites this paper
• A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9-15%: DUAL HIGH Trial.

  2023cites this paper
• Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes in Adriatic Region Countries: ENSURE-ADR, a Real-World Study

  2023cites this paper
• 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association

  2023cites this paper
• A Relative Cost of Control Analysis of IDegLira versus Other Forms of Basal Insulin Intensification in Mexico

  2023influential citation
• Comparison of the efficacy and safety of commercially available fixed ratio combinations of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) - a network meta-analysis.

  2023cites this paper
• Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients

  2023cites this paper
• Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes

  2023cites this paper
• Efficacy and safety of fixed‐ratio combination insulin degludec/liraglutide in type 2 diabetes: A systematic review and meta‐analysis of randomised controlled trials

  2023cites this paper
• Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes

  2023cites this paper
• Fixed-Ratio combinations (Basal Insulin Plus GLP-1RA) in Type 2 diabetes. An analytical review of pivotal clinical trials

  2023cites this paper
• Restoration of blood vessel regeneration in the era of combination SGLT2i and GLP-1RA therapy for diabetes and obesity.

  2023cites this paper
• Therapeutic efficacy of liraglutide versus metformin in modulating the gut microbiota for treating type 2 diabetes mellitus complicated with nonalcoholic fatty liver disease

  2023cites this paper
• Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?

  2023cites this paper
• Effect of the glucagon‐like peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes

  2023cites this paper
• Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting

  2022cites this paper
• During the Effectiveness of IDegLira in Type-2 Diabetes Patients During the COVID-19 Pandemic: A Teleconsultation Follow-up

  2022cites this paper
• Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2022cites this paper
• Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

  2022cites this paper
• De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes

  2022cites this paper
• Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis

  2022cites this paper
• Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes: a retrospective cohort study

  2022cites this paper
• Switching to a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) is associated with improved glycaemic control in a real-world population with type 2 diabetes mellitus in the United Arab Emirates: Results from the multicentre, prospective INTENSIFY study.

  2022cites this paper
• Initiation of the Fixed Combination IDegLira in Patients with Type 2 Diabetes on Prior Injectable Therapy: Insights from the EASY French Real-World Study

  2022cites this paper
• Transitioning from basal–bolus or premix insulin therapy to a combination of basal insulin and glucagon‐like peptide‐1 receptor agonist in people with type 2 diabetes

  2022cites this paper
• IDegLira for the Real-World Treatment of Type 2 Diabetes in Italy: Protocol and Interim Results from the REX Observational Study

  2022cites this paper
• Meta-analysis of seven heterogeneous studies on liraglutide add-on therapy in patients with type 2 diabetes mellitus treated with insulin.

  2022cites this paper
• Effects of Metabolic Medicine and Metabolic Surgery on Patient-Reported Outcomes Among Patients with Type 2 Diabetes

  2022cites this paper
• Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM

  2022cites this paper
• Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus

  2022cites this paper
• Continuous Subcutaneous Insulin Infusion (CSII) Combined with Oral Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomized, Controlled Trials

  2022cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.

  2022cites this paper
• 2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association.

  2021cites this paper
• DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin

  2021cites this paper
• Advancing Therapy in Suboptimally Controlled Basal Insulin–Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial

  2021cites this paper
• Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care

  2021cites this paper
• Comparison of adverse effects among different GLP-1 receptor agonists added to basal insulin, and between GLP-1 receptor agonists and basal insulin versus Basal-plus or basal-bolus insulin in type 2 diabetes: A meta-analysis

  2021cites this paper
• Changed Diabetic Treatment from Multiple Daily Injection (MDI), Dulaglutide to Xultophy

  2021cites this paper
• Efficacy and safety of the fixed‐ratio combination of insulin degludec and liraglutide by baseline glycated hemoglobin, body mass index and age in Japanese individuals with type 2 diabetes: A subgroup analysis of two phase III trials

  2021cites this paper
• Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes

  2021cites this paper
• 2021 Clinical Practice Guidelines for Diabetes Mellitus in Korea

  2021cites this paper
• Effective and convenient treatment of Xultophy with lower doses for elderly diabetic patient

  2021cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.

  2021cites this paper
• Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population

  2021cites this paper
• An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus

  2021cites this paper
• Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK

  2021cites this paper
• Glycated haemoglobin reduction and fixed ratio combinations of analogue basal insulin and glucagon-like peptide-1 receptor agonists: A systematic review

  2021cites this paper
• Satisfactory Rapid Response to Xultophy Associated with Meal Tolerance Test (MTT) by Carbohydrate Loading

  2021cites this paper
• [Diagnosis, Prevention and Treatment of Cardiovascular Disease in People with Diabetes and Prediabetes].

  2021cites this paper
• Injectable combination therapies for the management of diabetes: an Indian perspective

  2020cites this paper
• The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial

  2020cites this paper
• Insulin degludec/liraglutide in type 2 diabetes: a profile of its use

  2020influential citation
• IRWIS (IDegLira Real world Indian Study): A Real-World Observational Study For Use of IDegLira In Indian Patients

  2020cites this paper
• The Administration of Xultophy for Diabetic Patients on Hemodialysis

  2020cites this paper
• Various Evidence-Based Effects of Insulin Degludec/Liraglutide (Ideglira) for Type 2 Diabetes Mellitus

  2020cites this paper
• Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes

  2020cites this paper
• Prevalence of Incretin-Mimetic and Sodium-Glucose-Transporter-2-Inhibitor Therapy in German Hospitalized Type-2 Diabetics Following Myocardial Revascularization: An Observational Study

  2020cites this paper
• Glycemic Variability, Oxidative Stress and Impact on Complications Related to Type 2 Diabetes Mellitus.

  2020cites this paper
• Patient‐reported outcomes in a study of human regular U‐500 insulin delivered by continuous subcutaneous insulin infusion or multiple daily injections in patients with type 2 diabetes

  2020cites this paper
• Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update - The User's Guide.

  2020cites this paper
• Fixed-Ratio Combinations of Basal Insulin and Glp-1ra in the Management of Type 2 Diabetes Mellitus: Highlight from Literature.

  2020cites this paper
• The efficacy and safety of Dipeptyl Peptidase-4 inhibitors compared to other Oral glucose-lowering medications in the treatment of type 2 diabetes.

  2020cites this paper
• Persistence with IDegLira in Patients in Clinical Practice: A Nationwide Observational Study in Sweden

  2020cites this paper
• How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?

  2020cites this paper
• Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon‐like peptide‐1 receptor agonists: a systematic literature review and indirect treatment comparison

  2020cites this paper
• Gastrointestinal adverse events with insulin glargine/lixisenatide fixed‐ratio combination versus glucagon‐like peptide‐1 receptor agonists in people with type 2 diabetes mellitus: A network meta‐analysis

  2020cites this paper
• Swiss Recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the Treatment of Type 2 Diabetes

  2020cites this paper
• Clinical Use of IDegLira: Initiation to Titration After Basal Insulin

  2020influential citation
• Transitioning to non-insulin therapy in a patient receiving high dose insulin.

  2020cites this paper
• Insulin degludec/liraglutide in type 2 diabetes: a profile of its use

  2020cites this paper
• Prevalence of Incretin-mimetic and Sodium-Glucose-Transporter-2-Inhibitor Therapy in Hospitalized Type-2-Diabetics following Myocardial Revascularization: an Observational Study

  2020cites this paper
• Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in Diabetic Patients Treated with the Combined Formulation Degludec–Liraglutide (Ideglira)

  2020cites this paper
• Glycemic Control Among Patients Newly Prescribed IDegLira Across Prior Therapy Group in US Real-World Practice

  2020cites this paper
• Analysis and reporting of adverse events in randomised controlled trials: a review

  2019cites this paper